# A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries

Study · id `cardio:ct-nct06539689` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06539689](<https://clinicaltrials.gov/study/NCT06539689>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06539689

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT06539689. Randomized; no masking; primary purpose treatment. Start 2024-06-04 (actual); primary completion 2026-12-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT06539689, source copy `cardio:ctgov-nct06539689-2024-08-06`, retrieved 2026-10-31)
- Started: 2024-06-04 (actual) (ClinicalTrials.gov record NCT06539689, source copy `cardio:ctgov-nct06539689-2024-08-06`, retrieved 2026-10-31)
- Primary completion: 2026-12-04 (anticipated) (ClinicalTrials.gov record NCT06539689, source copy `cardio:ctgov-nct06539689-2024-08-06`, retrieved 2026-10-31)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06539689, source copy `cardio:ctgov-nct06539689-2024-08-06`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06539689, source copy `cardio:ctgov-nct06539689-2024-08-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06539689-2024-08-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
- Acronym: SURF
- Condition: Peripheral Arterial Disease
- Condition: Stenosis
- Condition: Dissection
- Intervention (Device): Sperstent® peripheral spot stent system
- Intervention (Device): Everflex® self-expanding peripheral stent system
- Lead sponsor: FrontAce Scientific Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 988fac28e480cfb5d5542a9bbe346afda77b01776eca1f79facca7664adf8889
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
